Page last updated: 2024-12-08
3-(1h-indol-3-yl)pyrrolidine-2,5-dione
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
3-(1H-indol-3-yl)pyrrolidine-2,5-dione: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 363326 |
| CHEMBL ID | 1374439 |
| SCHEMBL ID | 45434 |
| MeSH ID | M0589067 |
Synonyms (27)
| Synonym |
|---|
| nsc-628183 |
| NCI60_009055 |
| SDCCGMLS-0041082.P002 |
| 3-(1h-indol-3-yl)-2,5-pyrrolidinedione |
| MLS000099368 , |
| smr000071516 |
| nsc628183 |
| 3-(1h-indol-3-yl)pyrrolidine-2,5-dione |
| 2,5-pyrrolidinedione, 3-(1h-indol-3-yl)- |
| STK996344 |
| F2147-1323 |
| AKOS003597099 |
| 10185-29-2 |
| HMS2388G15 |
| AB13798 |
| SCHEMBL45434 |
| VNQNEQQYAIPCAQ-UHFFFAOYSA-N |
| 3-(1h-indol-3-yl)-pyrrolidine-2,5-dione |
| cid_363326 |
| 3-(1h-indol-3-yl)pyrrolidine-2,5-quinone |
| bdbm73346 |
| CHEMBL1374439 |
| DTXSID60327048 |
| sr-01000248304 |
| SR-01000248304-1 |
| 3-indol-3-yl-pyrrolidine-2,5-dione |
| AMY441 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (4)
Potency Measurements
| Protein | Taxonomy | Measurement | Average (µ) | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Chain A, Beta-lactamase | Escherichia coli K-12 | Potency | 10.0000 | 0.0447 | 17.8581 | 100.0000 | AID485294 |
| lamin isoform A-delta10 | Homo sapiens (human) | Potency | 0.0035 | 0.8913 | 12.0676 | 28.1838 | AID1487 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) | IC50 (µMol) | 3.0000 | 0.0537 | 3.0757 | 10.0000 | AID1489353 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Activation Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| ORF73 | Human gammaherpesvirus 8 | EC50 (µMol) | 75.0000 | 0.0600 | 8.1346 | 32.1400 | AID435023 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (19)
Molecular Functions (5)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| electron transfer activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| heme binding | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| indoleamine 2,3-dioxygenase activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| metal ion binding | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| tryptophan 2,3-dioxygenase activity | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Ceullar Components (4)
| Process | via Protein(s) | Taxonomy |
|---|---|---|
| cytosol | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| smooth muscle contractile fiber | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| stereocilium bundle | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| cytoplasm | Indoleamine 2,3-dioxygenase 1 | Homo sapiens (human) |
| [Information is prepared from geneontology information from the June-17-2024 release] | ||
Bioassays (14)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1745845 | Primary qHTS for Inhibitors of ATXN expression | |||
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588499 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain A protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588501 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Lethal Factor Protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504810 | Antagonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID651635 | Viability Counterscreen for Primary qHTS for Inhibitors of ATXN expression | |||
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Current protocols in cytometry, Oct, Volume: Chapter 13 | Microsphere-based flow cytometry protease assays for use in protease activity detection and high-throughput screening. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2006 | Cytometry. Part A : the journal of the International Society for Analytical Cytology, May, Volume: 69, Issue:5 | Microsphere-based protease assays and screening application for lethal factor and factor Xa. |
| AID588497 | High-throughput multiplex microsphere screening for inhibitors of toxin protease, specifically Botulinum neurotoxin light chain F protease, MLPCN compound set | 2010 | Assay and drug development technologies, Feb, Volume: 8, Issue:1 | High-throughput multiplex flow cytometry screening for botulinum neurotoxin type a light chain protease inhibitors. |
| AID504812 | Inverse Agonists of the Thyroid Stimulating Hormone Receptor: HTS campaign | 2010 | Endocrinology, Jul, Volume: 151, Issue:7 | A small molecule inverse agonist for the human thyroid-stimulating hormone receptor. |
| AID1489353 | Inhibition of human recombinant IDO-1 using L-Trp as substrate after 15 mins by PDMAB-based assay | 2017 | Journal of medicinal chemistry, 12-14, Volume: 60, Issue:23 | Discovery of a Novel and Selective Indoleamine 2,3-Dioxygenase (IDO-1) Inhibitor 3-(5-Fluoro-1H-indol-3-yl)pyrrolidine-2,5-dione (EOS200271/PF-06840003) and Its Characterization as a Potential Clinical Candidate. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (7)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (14.29) | 29.6817 |
| 2010's | 5 (71.43) | 24.3611 |
| 2020's | 1 (14.29) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 12.29
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (12.29) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 7 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||